Skip to main content
Top
Published in: Journal of Translational Medicine 1/2017

Open Access 01-12-2017 | Research

Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases

Authors: Maria A. Pizzichetta, Daniela Massi, Mario Mandalà, Paola Queirolo, Ignazio Stanganelli, Vincenzo De Giorgi, Giovanni Ghigliotti, Stefano Cavicchini, Pietro Quaglino, Maria T. Corradin, Pietro Rubegni, Mauro Alaibac, Stefano Astorino, Fabrizio Ayala, Serena Magi, Laura Mazzoni, Maria Ausilia Manganoni, Renato Talamini, Diego Serraino, Giuseppe Palmieri, on behalf of the Italian Melanoma Intergroup (IMI)

Published in: Journal of Translational Medicine | Issue 1/2017

Login to get access

Abstract

Background

Nodular melanoma (NM) accounts for most thick melanomas and because of their frequent association with ulceration, fast growth rate and high mitotic rate, contribute substantially to melanoma-related mortality. In a multicentric series of 214 primary melanomas including 96 NM and 118 superficial spreading melanoma (SSM), histopathological features were examined with the aim to identify clinicopathological predictors of recurrence.

Methods

All consecutive cases of histopathologically diagnosed primary invasive SSM and NM during the period 2005–2010, were retrieved from the 12 participating Italian Melanoma Intergroup (IMI) centers. Each center provided clinico-pathological data such as gender, age at diagnosis, anatomical site, histopathological conventional parameters, date of excision and first melanoma recurrence.

Results

Results showed that NM subtype was significantly associated with Breslow thickness (BT) at multivariate analysis: [BT 1.01–2 mm (OR 7.22; 95% CI 2.73–19.05), BT 2.01–4 mm (OR 7.04; 95% CI 2.54–19.56), and BT > 4 mm (OR 51.78; 95% CI 5.65–474.86) (p < 0.0001)]. Furthermore, mitotic rate (MR) was significantly correlated with NM histotype: [(MR 3–5 mitoses/mm2 (OR 2.62; 95% CI 1.01–6.83) and MR > 5 mitoses/mm2 (OR 4.87; 95% CI 1.77–13.40) (p = 0.002)]. The risk of recurrence was not significantly associated with NM histotype while BT [BT 1.01–2.00 mm (HR 1.55; 95% CI 0.51–4.71), BT 2.01–4.00 mm (HR 2.42; 95% CI 0.89–6.54), BT > 4.00 mm. (HR 3.13; 95% CI 0.95–10.28) (p = 0.05)], mitotic rate [MR > 2 mitoses/mm2 (HR 2.34; 95% CI, 1.11–4.97) (p = 0.03)] and the positivity of lymph node sentinel biopsy (SNLB) (HR 2.60; 95% CI 1.19–5.68) (p = 0.007) were significantly associated with an increased risk of recurrence at multivariate analysis.

Conclusions

We found that NM subtype was significantly associated with higher BT and MR but it was not a prognostic factor since it did not significantly correlate with melanoma recurrence rate. Conversely, increased BT and MR as well as SNLB positivity were significantly associated with a higher risk of melanoma recurrence.
Literature
1.
go back to reference Fuglede NB, Brinck-Claussen UO, Deltour I, Boesen EH, Dalton SO, Johansen C. Incidence of cutaneous malignant melanoma in Denmark, 1978–2007. Br J Dermatol. 2011;2:349–53.CrossRef Fuglede NB, Brinck-Claussen UO, Deltour I, Boesen EH, Dalton SO, Johansen C. Incidence of cutaneous malignant melanoma in Denmark, 1978–2007. Br J Dermatol. 2011;2:349–53.CrossRef
2.
go back to reference UICC-TNM classification of malignant tumours. Eight edition, edited by Brierlev JD, Gospodarowicz MK and Wittekind C, 2017. UICC-TNM classification of malignant tumours. Eight edition, edited by Brierlev JD, Gospodarowicz MK and Wittekind C, 2017.
3.
go back to reference Liu W, Dowling JP, Murray WK, McArthur GA, Thompson JF, Wolfe R, et al. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol. 2006;142:1551–8.PubMed Liu W, Dowling JP, Murray WK, McArthur GA, Thompson JF, Wolfe R, et al. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol. 2006;142:1551–8.PubMed
5.
go back to reference Grob JJ, Richard MA, Gouvernet J, Avril MF, Delaunay M, Wolkenstein P, et al. The kinetics of the visible growth of a primary melanoma reflects the tumor aggressiveness and is an independent prognostic marker: a prospective study. Int J Cancer. 2002;102:34–8.CrossRefPubMed Grob JJ, Richard MA, Gouvernet J, Avril MF, Delaunay M, Wolkenstein P, et al. The kinetics of the visible growth of a primary melanoma reflects the tumor aggressiveness and is an independent prognostic marker: a prospective study. Int J Cancer. 2002;102:34–8.CrossRefPubMed
6.
go back to reference Demierre MF, Chung C, Miller DR, Geller AC. Early detection of thick melanomas, in the United States: beware of the nodular subtype. Arch Dermatol. 2005;141:745–50.PubMed Demierre MF, Chung C, Miller DR, Geller AC. Early detection of thick melanomas, in the United States: beware of the nodular subtype. Arch Dermatol. 2005;141:745–50.PubMed
7.
go back to reference Shaikh WR, Xiong M, Weinstock MA. The contribution of nodular subtype to melanoma mortality in the United States, 1978–2007. Arch Dermatol. 2012;148:30–6.CrossRefPubMed Shaikh WR, Xiong M, Weinstock MA. The contribution of nodular subtype to melanoma mortality in the United States, 1978–2007. Arch Dermatol. 2012;148:30–6.CrossRefPubMed
9.
go back to reference Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef
10.
go back to reference Cox DR. Regression model and life-tables. J R Stat Soc B. 1972;34:178–220. Cox DR. Regression model and life-tables. J R Stat Soc B. 1972;34:178–220.
11.
go back to reference Bergenmar M, Hansson J, Brandberg Y. Detection of nodular and superficial spreading melanoma with tumor thickness ≤ 2.00 mm—an interview study. Eur J Cancer Prev. 2002;11:49–55.CrossRefPubMed Bergenmar M, Hansson J, Brandberg Y. Detection of nodular and superficial spreading melanoma with tumor thickness ≤ 2.00 mm—an interview study. Eur J Cancer Prev. 2002;11:49–55.CrossRefPubMed
12.
go back to reference Carli P, De Giorgi V, Palli D, Maurichi A, Mulas P, Orlandi C, et al. Patterns of detection of superficial spreading and nodular-type melanoma: a multicenter Italian study. Dermatol Surg. 2004;30:1371–6.PubMed Carli P, De Giorgi V, Palli D, Maurichi A, Mulas P, Orlandi C, et al. Patterns of detection of superficial spreading and nodular-type melanoma: a multicenter Italian study. Dermatol Surg. 2004;30:1371–6.PubMed
13.
go back to reference Warycha MA, Christos PJ, Mazumdar M, Darvishian F, Shapiro RL, Berman RS, et al. Changes in the presentation of nodular and superficial spreading melanomas over 35 years. Cancer. 2008;113:3341–8.CrossRefPubMedPubMedCentral Warycha MA, Christos PJ, Mazumdar M, Darvishian F, Shapiro RL, Berman RS, et al. Changes in the presentation of nodular and superficial spreading melanomas over 35 years. Cancer. 2008;113:3341–8.CrossRefPubMedPubMedCentral
14.
go back to reference Zalaudek I, Marghoob AA, Scope A, Leinweber B, Ferrara G, Hofmann-Wellenhof R, et al. Three roots of melanoma. Arch Dermatol. 2008;144:1375–8.PubMed Zalaudek I, Marghoob AA, Scope A, Leinweber B, Ferrara G, Hofmann-Wellenhof R, et al. Three roots of melanoma. Arch Dermatol. 2008;144:1375–8.PubMed
15.
go back to reference Tas F, Erturk K. Tumour infiltrating lymphocytes (TILs) may be only an independent predictor of nodal involvement but not for recurrence and survival in cutaneous melanoma patients. Cancer Invest. 2017;35:501–5.CrossRefPubMed Tas F, Erturk K. Tumour infiltrating lymphocytes (TILs) may be only an independent predictor of nodal involvement but not for recurrence and survival in cutaneous melanoma patients. Cancer Invest. 2017;35:501–5.CrossRefPubMed
16.
go back to reference Egger ME, Dunki-Jacobs EM, Callender GG, Quillo AR, Scoggins CR, Martin RCG II, et al. Outcomes and prognostic factors in nodular melanomas. Surgery. 2012;152:652–60.CrossRefPubMed Egger ME, Dunki-Jacobs EM, Callender GG, Quillo AR, Scoggins CR, Martin RCG II, et al. Outcomes and prognostic factors in nodular melanomas. Surgery. 2012;152:652–60.CrossRefPubMed
17.
go back to reference Deshmane V, Kalloli M, Chikaraddi S, Keerthi BR, Krishnappa R, et al. Predictive factors for loco regional recurrence and distant metastasis following primary surgical treatment of cutaneous melanoma. Indian J Dermatol (Dermatol Intern Med). 2014;59:241–6.CrossRef Deshmane V, Kalloli M, Chikaraddi S, Keerthi BR, Krishnappa R, et al. Predictive factors for loco regional recurrence and distant metastasis following primary surgical treatment of cutaneous melanoma. Indian J Dermatol (Dermatol Intern Med). 2014;59:241–6.CrossRef
19.
go back to reference Mandala’M, Galli F, Cattaneo L, Merelli B, Rulli E, Ribero S, et al. Mitotic rate correlates with sentinel lymph node status, and out come in cutaneous melanoma greater than 1 mm in thickness: a multi-institutional study of 1524 cases. J Am Acad Dermatol. 2017;76:264–73.CrossRef Mandala’M, Galli F, Cattaneo L, Merelli B, Rulli E, Ribero S, et al. Mitotic rate correlates with sentinel lymph node status, and out come in cutaneous melanoma greater than 1 mm in thickness: a multi-institutional study of 1524 cases. J Am Acad Dermatol. 2017;76:264–73.CrossRef
20.
go back to reference Faut M, Wevers KP, Van Ginkel RJ, Diercks GFH, Hoekstra HJ, Kruijff S, et al. Nodular histologic subtype and ulceration are tumor factors associated with high risk of recurrence in sentinel node-negative melanoma patients. Ann Surg Oncol. 2016. https://doi.org/10.1245/s10434-016-5566-8. Faut M, Wevers KP, Van Ginkel RJ, Diercks GFH, Hoekstra HJ, Kruijff S, et al. Nodular histologic subtype and ulceration are tumor factors associated with high risk of recurrence in sentinel node-negative melanoma patients. Ann Surg Oncol. 2016. https://​doi.​org/​10.​1245/​s10434-016-5566-8.
21.
go back to reference O’Connel EP, O’Leary DP, Fogarty K, Khan ZJ, Redmond HP. Predictors and patterns of melanoma recurrence following a negative sentinel lymph node biopsy. Melanoma Res. 2016;26:66–70.CrossRef O’Connel EP, O’Leary DP, Fogarty K, Khan ZJ, Redmond HP. Predictors and patterns of melanoma recurrence following a negative sentinel lymph node biopsy. Melanoma Res. 2016;26:66–70.CrossRef
22.
go back to reference Brauer JA, Wriston CC, Troxel AB, Elenitsas R, Shin DB, Guerry D, Ming ME. Characteristics associated with early and late melanoma metastases. Cancer. 2010;116:415–23.CrossRefPubMed Brauer JA, Wriston CC, Troxel AB, Elenitsas R, Shin DB, Guerry D, Ming ME. Characteristics associated with early and late melanoma metastases. Cancer. 2010;116:415–23.CrossRefPubMed
24.
go back to reference Gualano MR, Osella A, Scaioli G, Marra E, Bert F, Faure E, Baduael ES, Balagna E, Quaglino P, Fierro MT, Siliquini R, Ribero S. Prognostic role of histologic regression in primary cutaneous melanoma: a systematic review and Meta-analysis. Br J Dermatol. 2017. https://doi.org/10.1111/bjd.15552.PubMed Gualano MR, Osella A, Scaioli G, Marra E, Bert F, Faure E, Baduael ES, Balagna E, Quaglino P, Fierro MT, Siliquini R, Ribero S. Prognostic role of histologic regression in primary cutaneous melanoma: a systematic review and Meta-analysis. Br J Dermatol. 2017. https://​doi.​org/​10.​1111/​bjd.​15552.PubMed
Metadata
Title
Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases
Authors
Maria A. Pizzichetta
Daniela Massi
Mario Mandalà
Paola Queirolo
Ignazio Stanganelli
Vincenzo De Giorgi
Giovanni Ghigliotti
Stefano Cavicchini
Pietro Quaglino
Maria T. Corradin
Pietro Rubegni
Mauro Alaibac
Stefano Astorino
Fabrizio Ayala
Serena Magi
Laura Mazzoni
Maria Ausilia Manganoni
Renato Talamini
Diego Serraino
Giuseppe Palmieri
on behalf of the Italian Melanoma Intergroup (IMI)
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2017
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-017-1332-3

Other articles of this Issue 1/2017

Journal of Translational Medicine 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.